文献速递慢阻肺呼吸危重症与机械通气

家庭经鼻高流量氧疗用于稳定期高碳酸血症性慢阻肺:一项随机临床试验

Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

本研究纳入104例接受长期氧疗的稳定期高碳酸血症性慢阻肺患者,随机分为经鼻高流量氧疗联合长期氧疗组与长期氧疗组,主要终点为中重度急性加重率。结果显示经鼻高流量氧疗显著降低中重度急性加重率并延长无急性加重时间,同时改善生活质量评分、外周血氧饱和度和部分肺功能参数,未发现安全性问题。

要点

  • 经鼻高流量氧疗可显著降低稳定期高碳酸血症性慢阻肺患者中重度急性加重率。
  • 经鼻高流量氧疗延长了首次中重度急性加重的时间,并改善生活质量与部分肺功能参数。
  • 对于有急性加重史的稳定期高碳酸血症性慢阻肺患者,经鼻高流量氧疗是合理的治疗选择。

核心结论

  • 经鼻高流量氧疗是稳定期高碳酸血症性慢阻肺且有急性加重史患者的合理治疗选择。

研究设计与样本

  • 随机对照试验纳入104例年龄≥40岁、日间高碳酸血症(GOLD 2-4期)且接受长期氧疗(≥16 h/d,≥1个月)的患者。
  • 患者随机分为经鼻高流量氧疗联合长期氧疗组与长期氧疗组,主要终点为中重度急性加重率。

主要发现

  • 经鼻高流量氧疗显著降低中重度急性加重率,未调整平均计数为1.0 vs. 2.5,组间调整平均计数比值(95%CI)为2.85(1.48-5.47)。
  • 长期氧疗组首次中重度急性加重的中位时间为25(14.1-47.4)周,经鼻高流量氧疗联合长期氧疗组未达到。
  • 经鼻高流量氧疗显著改善健康相关生活质量评分、外周血氧饱和度和特定肺功能参数,未发现安全性问题。

临床怎么用

  • 对于稳定期高碳酸血症性慢阻肺且长期氧疗、有急性加重史的患者,可考虑家庭经鼻高流量氧疗以降低急性加重风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The long-term effects of using a high-flow nasal cannula for chronic hypercapnic respiratory failure caused by chronic obstructive pulmonary disease remain unclear. Objectives: To assess whether long-term high-flow nasal cannula use reduces the number of exacerbations and improves other physiological parameters in patients with chronic hypercapnic respiratory failure caused by chronic obstructive pulmonary disease. Methods: We enrolled 104 participants (aged ⩾40 yr) with daytime hypercapnia (Global Initiative for Chronic Obstructive Lung Disease stages 2-4) receiving long-term oxygen therapy (⩾16 h/d for ⩾1 mo) and randomly assigned them to high-flow nasal cannula/long-term oxygen therapy and long-term oxygen therapy groups. The primary endpoint was the moderate or severe exacerbation rate. We compared changes from baseline in arterial blood gas values, peripheral oxygen saturation, pulmonary function, health-related quality-of-life scores, and the 6-minute-walk test. Measurements and Main Results: High-flow nasal cannula use significantly reduced the rate of moderate/severe exacerbations (unadjusted mean count 1.0 vs. 2.5, a ratio of the adjusted mean count between groups [95% confidence interval] of 2.85 [1.48-5.47]) and prolonged the duration without moderate or severe exacerbations. The median time to first moderate or severe exacerbation in the long-term oxygen therapy group was 25 (14.1-47.4) weeks; this was not reached in the high-flow nasal cannula/long-term oxygen therapy group. High-flow nasal cannula use significantly improved health-related quality of life scores, peripheral oxygen saturation, and specific pulmonary function parameters. No safety concerns were identified. Conclusions: A high-flow nasal cannula is a reasonable therapeutic option for patients with stable hypercapnic chronic obstructive pulmonary disease and a history of exacerbations. Clinical trial registered with www.umin/ac.jp (UMIN000028581) and www.clinicaltrials.gov (NCT03282019).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Nagata, Horie, Chohnabayashi, et al. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 35771533. doi:10.1164/rccm.202201-0199OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。